Innocan Pharma Announces Private Placement of Units at a 9% Prime Above Share Price
HERZLIYA, Israel, and CALGARY, Alberta — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”) is pleased to announce that it intends to complete a non-brokered private placement of up to 17,220,000 units of the Company (the “Units”) at a price of C$0.23 per Unit for gross proceeds up to C$3,960,600 (the “Offering”). The Offering is expected to close on or around July 20, 2023. Each Unit will be comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); (ii) one-half of one (1) Class A common share purchase warrant (each whole Class A common share purchase warrant, a “Class A Warrant”); and (iii) one-half of one (1) Class B common share purchase warrant (each whole Class B common share purchase warrant, a “Class B Warrant”). Each Class A Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.29 for a period of three (3) years from the date of issuance. Each Class B Warrant wi...